Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin and Frontline Chemotherapy in Young Adults With Newly Diagnosed B-Cell ALL
NCT03150693Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2017
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Cancer and Leukemia Group B. Started Sep 2017; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03150693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150693.